Investment: Problems under the surface at Zeneca
Friday 07 August 1998
It has a decent drugs portfolio - its asthma treatment Accolate is still the star performer - backed up by a pipeline with a couple of potential best-sellers. The agrochemicals division, which has been a drag on earnings for some time, is set to benefit from recent restructuring, with fungicides already delivering growth.
Add a problem-free balance sheet and you can see why the market believes Zeneca is strong enough to keep its promise of growing underlying earnings by 15 per cent a year.
Yesterday's first-half results, which showed a 2 per cent slide in profits to pounds 654m after a heavy hit from sterling, Asia and the millennium bug, did little to dent this belief. The shares firmed 15p to 2280p after a pretty poor run in the weeks leading up to the figures.
So can Zeneca be discharged with a clean bill of health? Not really. If investors scratch the surface, they will see that some of the star drugs - including two blockbusters, the hypertension treatment Zestril and the cancer drug Novaldex - are set to lose patent protection in 2002. The new compounds which were supposed to replace them, notably the schizophrenia drug Seroquel, have got off to a slow start while the mature ones will suffer from increased competition.
At the same time, the agrochemicals division will be hit by difficult market conditions and shrinking margins. True, Zeneca could be taken over by one of the pharmaceutical giants, but no credible suitor willing to pay a premium has materialised despite years of speculation. And with the shares trading at almost 30 times expected 1998 earnings of around pounds 1.1bn - a 60 per cent premium to the market - the prescription is: sell into strength.
- 1 Nigel Farage: Me vs Russell Brand on Question Time – he's got the chest hair but where are his ideas?
- 2 Harry Potter fans can apply to the Hogwarts-inspired College of Wizardry
- 3 Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
- 4 Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
- 5 Orange Wednesdays are no more
Weather bomb in pictures: Storms cuts power for tens of thousands – and snow is on the way
Jessica Chambers: 19-year-old woman 'doused with lighter fluid and burned alive' in the US
Russell Brand calls Nigel Farage 'poundshop Enoch Powell' in BBC Question Time debate
Russell Brand was rendered speechless on Question Time by this man
Fury at Airbus after it hints the super-jumbo may be mothballed
Disgruntled RBS worker writes hilarious open letter to Russell Brand after anti-capitalist publicity stunt leaves him hungry
Shock poll shows voters believe Ukip is to the left of the Tories
Nigel Farage's approval rating hits 'record low' as popularity suffers in wake of Ukip sex scandal
Nigel Farage defends Kerry Smith 'ch***y' comment: 'If you are going for a Chinese, what do you say you’re going for?'
Ukip candidate jokes about 'shooting peasants' in racist and homophobic rant
Pakistan school attack live: Taliban kill at least 132 children in 'horrifying' massacre
iJobs Money & Business
$200 - $350 per annum: Carlton Senior Appointments: Managing Producer Office...
$125 - $225 per annum: Carlton Senior Appointments: San Fran - Investment Advi...
Up to £70,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...
Up to £65,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...